Supplementary Tables from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Ziju Y. Xu-Monette(The University of Texas MD Anderson Cancer Center), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), George Z. Rassidakis(Karolinska University Hospital), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Eric D. Hsi(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Raúl Torres(Spanish National Cancer Research Centre), Min Xiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Wayne Tam(Cornell University), Qingyan Au(NeoGenomics (United States)), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Sandra Rodríguez(Spanish National Cancer Research Centre), Gordon J. Freeman(Dana-Farber Cancer Institute), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Yong Li(Baylor College of Medicine), Jing Wang, Hongwei Zhang(Anhui Medical University), Bing Xu(Delft University of Technology), Yi Miao(Changchun Gold Research Institute (China)), Xiaohong Tan, Raghav Padmanabhan(NeoGenomics (United States)), Hua You(Third People's Hospital of Hangzhou), Lan V. Pham(Pharmacyclics (United States)), L. Jeffrey Medeiros(Delaware Division of Libraries), Nicholas Hoe(NeoGenomics (United States)), Jane N. Winter(Northwestern University)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
|Cell|2016|2.4k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k